Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Open access

Abstract

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms in an individual patient 1-3. Previous case reports and small case series have suggested that liquid biopsy (specifically, cell-free DNA (cfDNA)) may better capture the heterogeneity of acquired resistance 4-8. However, the effectiveness of cfDNA versus standard single-lesion tumor biopsies has not been directly compared in larger-scale prospective cohorts of patients following progression on targeted therapy. Here, in a prospective cohort of 42 patients with molecularly defined gastrointestinal cancers and acquired resistance to targeted therapy, direct comparison of postprogression cfDNA versus tumor biopsy revealed that cfDNA more frequently identified clinically relevant resistance alterations and multiple resistance mechanisms, detecting resistance alterations not found in the matched tumor biopsy in 78% of cases. Whole-exome sequencing of serial cfDNA, tumor biopsies and rapid autopsy specimens elucidated substantial geographic and evolutionary differences across lesions. Our data suggest that acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in an individual patient may represent the 'rule' rather than the 'exception'. These findings have profound therapeutic implications and highlight the potential advantages of cfDNA over tissue biopsy in the setting of acquired resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0561-9

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 528

Metadata

Authors
Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., Hanna, M., Slowik, K., Utro, F., Pinto, C. J., Wong, A., Danysh, B. P., de la Cruz, F. F., Fetter, I. J., Nadres, B., Shahzade, H. A., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Giantonio, B., Murphy, J. E., Nipp, R. D., Roeland, E., Ryan, D. P., Weekes, C. D., Kwak, E. L., Faris, J. E., Wo, J. Y., Aguet, F., Dey-Guha, I., Hazar-Rethinam, M., Dias-Santagata, D., Ting, D. T., Zhu, A. X., Hong, T. S., Golub, T. R., Iafrate, A. J., Adalsteinsson, V. A., Bardelli, A., Parida, L., Juric, D., Getz, G., & Corcoran, R. B.
Affiliations
  • Harvard University (US)
  • Broad Institute (US)
  • IBM (United States) (US)
  • Candiolo Cancer Institute (IT)
Corresponding author
  • Getz, Gad
  • Corcoran, Ryan B.
Venue
Nature Medicine
Published
2019-09
Volume
25
Issue
9
Pages
1415-1421
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2972422665
Cited by
518
References
63
Citations by year
2026: 35 · 2025: 60 · 2024: 63 · 2023: 80 · 2022: 94 · 2021: 96 · 2020: 77 · 2019: 10
FWCI
22.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Celgene
  • Agios Pharmaceuticals
  • MacroGenics
  • Ministero della Salute
  • Eisai
  • Associazione Italiana per la Ricerca sul Cancro
  • Plexxikon
  • National Institutes of Health
  • Genentech
  • EMD Serono
  • Pharmacyclics
  • Foundation Medicine
  • National Cancer Institute (P50CA127003, R01CA208437, U54CA224068, K08CA166510, K12CA087723)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
liquid biopsy, cell-free DNA, tumor heterogeneity, acquired drug resistance, gastrointestinal cancer, targeted therapy resistance, tumor subclones, circulating tumor DNA, tissue biopsy comparison, resistance mechanisms
MeSH terms
Exome Sequencing, Cell-Free Nucleic Acids, Liquid Biopsy, Autopsy, DNA, Neoplasm, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Mutation, Cohort Studies, Genetic Heterogeneity, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. https://app.cochat.ai/papers/10.1038/s41591-019-0561-9
The paper
Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., Hanna, M., Slowik, K., Utro, F., Pinto, C. J., Wong, A., Danysh, B. P., de la Cruz, F. F., Fetter, I. J., Nadres, B., . . . Corcoran, R. B. (2019). Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. https://doi.org/10.1038/s41591-019-0561-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.